Summary
Eli Lilly and Company (LLY) filed an 8-K on January 31, 2017, to report its financial results for the fourth quarter and full fiscal year ended December 31, 2016. The filing primarily serves to incorporate by reference a press release (Exhibit 99.1) that details these operational results. While the 8-K itself does not contain the specific financial figures, it signifies the official public release of this information. Investors should refer to the attached press release for comprehensive details on Lilly's financial performance, including revenue, earnings, and any forward-looking guidance provided for the upcoming fiscal year. This report is crucial for understanding the company's recent performance trajectory and its outlook, which are key factors in investment decisions.
Key Highlights
- 1Eli Lilly & Co. (LLY) filed an 8-K on January 31, 2017, reporting Q4 and Full Year 2016 financial results.
- 2The primary purpose of the 8-K filing is to include a press release (Exhibit 99.1) with the detailed financial results.
- 3The press release, dated January 31, 2017, contains unaudited operating results for the periods ending December 31, 2016.
- 4Information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act, nor incorporated by reference into registration statements, unless expressly stated.
- 5Investors are directed to Exhibit 99.1 for specific financial data and operational performance.
- 6The filing signifies the official disclosure of Lilly's year-end and fourth-quarter financial performance for 2016.